^
    1d
    Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=456, Recruiting, Sanofi | Trial completion date: Nov 2026 --> Feb 2027 | Trial primary completion date: Nov 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed
    1d
    The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer. (PubMed, Invest New Drugs)
    The incorporation of a 5-day continuous intravenous infusion of rh-endostatin into platinum-based doublet chemotherapy has demonstrated both safety and efficacy in the treatment of advanced NSCLC. Furthermore, the baseline serum levels of CEA may potentially function as a predictor for the efficacy of rh-endostatin when combined with chemotherapy in NSCLC patients.
    Clinical • Journal • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    paclitaxel • pemetrexed
    1d
    Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors. (PubMed, Front Oncol)
    This retrospective study used a nationwide electronic health record-derived deidentified database to select adult patients with advanced nonsquamous NSCLC, evidence of EGFR exon 19 deletion or L858R mutation, and ECOG performance status of 0-2 who initiated platinum-containing chemotherapy, with or without concomitant immunotherapy, from 1-January-2011 to 30-June-2020 following receipt of any EGFR TKI as first-line therapy or, alternatively, a first- or second-generation EGFR TKI (erlotinib, afatinib, gefitinib, dacomitinib) as first-line therapy followed by the third-generation EGFR TKI osimertinib as second-line therapy. Median OS was 10.3 months (95% CI, 8.1-13.9) from pemetrexed-platinum initiation and 12.4 months (95% CI, 10.2-15.2) from platinum initiation; 12-month survival rates were 48% and 51%, respectively; 260 patients (84%) had died by the end of the study. The suboptimal survival outcomes recorded in this study demonstrate the unmet need to identify more effective subsequent treatment regimens for patients with EGFR-mutated advanced nonsquamous NSCLC after EGFR TKI resistance develops.
    Journal • Real-world evidence • IO biomarker • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • pemetrexed • Vizimpro (dacomitinib)
    1d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    3d
    TREBLE: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=8, Terminated, EQRx International, Inc. | Phase classification: P3b --> P3
    Phase classification • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Ameile (aumolertinib)
    3d
    Phase III Study of AK112 for NSCLC Patients (clinicaltrials.gov)
    P3, N=420, Recruiting, Summit Therapeutics
    New P3 trial • Metastases
    |
    carboplatin • pemetrexed • ivonescimab (AK112)
    3d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, Taipei Veterans General Hospital, Taiwan | Trial completion date: May 2025 --> Jun 2027 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • pemetrexed
    4d
    Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Effector Therapeutics | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • pemetrexed • tomivosertib (eFT508)
    4d
    ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (clinicaltrials.gov)
    P2, N=95, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    5d
    Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • ivonescimab (AK112)
    6d
    Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Effector Therapeutics | N=180 --> 68
    Enrollment change • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • pemetrexed • tomivosertib (eFT508)
    9d
    A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    cisplatin • carboplatin • pemetrexed • HRS-4642 • SHR-A1921 • adebrelimab (SHR-1316)
    9d
    AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (clinicaltrials.gov)
    P1, N=500, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lumakras (sotorasib) • pemetrexed • AMG 193
    9d
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1/2, N=1126, Recruiting, Amgen | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    10d
    Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2
    Phase classification • Combination therapy • Surgery • Metastases
    |
    cisplatin • carboplatin • pemetrexed • methoxyamine (TRC102)
    10d
    A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=46, Completed, Akeso | Active, not recruiting --> Completed | Trial completion date: Apr 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR wild-type
    |
    carboplatin • paclitaxel • pemetrexed • Kaitanni (cadonilimab)
    11d
    A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=428, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    cisplatin • carboplatin • pemetrexed • izalontamab brengitecan (BL-B01D1)
    12d
    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (clinicaltrials.gov)
    P3, N=398, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial • Combination therapy • EGFR exon 20 • Metastases
    |
    cisplatin • Tagrisso (osimertinib) • pemetrexed • becotarug (JMT101)
    12d
    ALK-PPL: A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (clinicaltrials.gov)
    P2, N=45, Recruiting, Centro di Riferimento Oncologico - Aviano
    New P2 trial
    |
    cisplatin • carboplatin • Lorbrena (lorlatinib) • pemetrexed
    12d
    BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=401, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    13d
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    14d
    Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up. (PubMed, J Thorac Oncol)
    P3; With ∼5 years of follow-up, pembrolizumab plus chemotherapy provided clinically meaningful and durable improvements in survival outcomes versus chemotherapy alone in patients with previously untreated metastatic NSCLC with PD-L1 TPS <1%. These results continue to support pembrolizumab plus chemotherapy as a standard of care in this patient population.
    Journal • Retrospective data • Tumor proportion score • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    16d
    Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Rachel Sanborn | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • etoposide IV
    17d
    Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (clinicaltrials.gov)
    P1, N=492, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Aug 2024 | Trial primary completion date: Oct 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
    17d
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov)
    P1, N=830, Recruiting, Merck Sharp & Dohme LLC | N=450 --> 830
    Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084
    17d
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov)
    P3, N=780, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • sacituzumab tirumotecan (MK-2870)
    18d
    Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC (clinicaltrials.gov)
    P3, N=48, Recruiting, Maximilian Diehn | Trial completion date: Mar 2026 --> Apr 2028 | Trial primary completion date: Mar 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab) • pemetrexed
    18d
    SPECTRUM: Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) (clinicaltrials.gov)
    P2, N=28, Recruiting, Seoul National University Hospital | Trial completion date: Feb 2024 --> Feb 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab) • pemetrexed
    20d
    DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, University of Alabama at Birmingham
    New P2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    21d
    Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations. (PubMed, Cancers (Basel))
    Contrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. IC median Progression Free Survival (mPFS) was 6.48 months, EC mPFS was 10.75 months, and median Overall Survival 11.47 months. ABCP in real-life patients with brain metastases (treated or untreated) was feasible and showed similar efficacy to that described in patients without actionable mutations treated with upfront chemo-immunotherapy.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • paclitaxel • pemetrexed
    23d
    A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL). (PubMed, Front Oncol)
    The results of the PEMBROREAL study have shown that the combined treatment of pembrolizumab with pemetrexed and platinum is effective for metastatic non-squamous NSCLC, even for patients with PD-L1 levels below 50%, despite the differences in patient demographics and pathological features compared to the Keynote-189 study. The adverse events reported during the study were more typical of chemotherapy treatment rather than immunotherapy, and physicians were able to manage them easily.
    Observational data • Retrospective data • Journal • Real-world evidence • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • pemetrexed
    25d
    DESTINY-Lung04: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations (clinicaltrials.gov)
    P3, N=450, Recruiting, AstraZeneca | N=264 --> 450 | Trial primary completion date: Jan 2025 --> Jun 2025
    Enrollment change • Trial primary completion date • HER2 exon 20 • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
    25d
    Pan Tumor Rollover Study (clinicaltrials.gov)
    P2, N=1500, Recruiting, Bristol-Myers Squibb | N=800 --> 1500 | Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2025 --> Aug 2029
    Enrollment change • Trial completion date • Trial primary completion date • Pan tumor
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • 5-fluorouracil • Sutent (sunitinib) • temozolomide • capecitabine • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • Rubraca (rucaparib) • Stivarga (regorafenib) • pemetrexed • oxaliplatin • Darzalex (daratumumab) • leucovorin calcium • Opdualag (nivolumab/relatlimab)
    26d
    BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=1000, Recruiting, Hoffmann-La Roche | Trial completion date: Apr 2024 --> Aug 2028 | Trial primary completion date: Apr 2024 --> Aug 2028
    Trial completion date • Trial primary completion date • Tumor mutational burden • Metastases
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)
    26d
    A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) (clinicaltrials.gov)
    P2, N=217, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed
    27d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=720, Recruiting, Gilead Sciences | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    27d
    MCC-21-NEURO-11: Pembro+Chemo in Brain Mets (clinicaltrials.gov)
    P2, N=3, Active, not recruiting, John L. Villano, MD, PhD | Trial primary completion date: Feb 2024 --> Jun 2023
    Trial primary completion date
    |
    PD-1 (Programmed cell death 1)
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    27d
    Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, National Cancer Institute (NCI) | N=78 --> 42
    Enrollment change • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)
    27d
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    30d
    NRG-LU002: Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=218, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2031 --> Dec 2028 | Trial primary completion date: Oct 2026 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • erlotinib • gemcitabine • docetaxel • pemetrexed
    30d
    Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov)
    P3, N=61, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=262 --> 61 | Trial completion date: May 2025 --> Sep 2026 | Trial primary completion date: May 2025 --> Sep 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • pemetrexed • Inlyta (axitinib) • vidutolimod (CMP-001) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    30d
    SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=117, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy
    |
    cisplatin • pemetrexed • Recentin (cediranib)